secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056871
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences Q1 net loss $21.7M; cash $179.8M; clinical trials on track
------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities totaled $179.8M as of March 31, 2024, down from $201.4M at Dec 31, 2023.
- Net loss $21.7M ($0.30 per share) vs $22.2M ($0.31) in Q1 2023; R&D expenses $17.2M, G&A $6.5M.
- PALIZADE Phase 2b for lupus nephritis actively enrolling; topline data expected mid-2026.
- PORTOLA Phase 2a for autoimmune hepatitis enrolling; topline data expected mid-2025.
- KZR-261 dose expansion in melanoma enrolling; initial study data expected by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024056871/0000950170-24-056871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024056871/kzr-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer